Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01009216 | A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid | PHASE1 | COMPLETED | 12 | — | — | Oct 1, 2009 | Nov 1, 2010 | Dec 14, 2010 | 1 | United States |
| NCT00968422 | A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects | PHASE1 | COMPLETED | 28 | — | — | Aug 1, 2009 | - | Nov 3, 2010 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| ABT-384 | EXPERIMENTAL | - |
| Low dose ABT-384 | EXPERIMENTAL | - |
| Mid dose ABT-384 | EXPERIMENTAL | - |
| High dose ABT-384 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ABT-384 | DRUG | Doses will be administered daily for 5 days. |
| Matching placebo to ABT-384 | DRUG | Doses will be administered daily for 21 days |
Inclusion Criteria: * Age is between 18 and 55 years * Judged to be in a condition of general good health based on the results of medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG Exclusion Criteria: * Use of protocol-prohibited medications within 2 weeks pr...